In which cases would you consider early transition to DOAC (within 72 hours) for hospitalized patients with intermediate or high risk PE?

Two DOACs are FDA-approved for early use (within 72 hrs), rivaroxaban and apixaban. The PEITHO-2 dabigatran cohort study included no comparison group (its authors called it a "trial"?) and required "72 hrs" parenteral anticoagulant before dabigatran but the small print in its Lancet Haematology show...

The PEITHO-2 trial of early (after 72 hours) switch to oral anticoagulation in patients with acute intermediate-risk pulmonary embolism showed that the primary outcome of recurrent symptomatic venous thromboembolism within 6 months only occurred in patients with intermediate-high risk (3% of the pop...